TELA Bio Amends 8-K to Disclose Executive Compensation Change

What Happened

• TELA Bio, Inc. filed an amendment to its Current Report on Form 8-K on August 13, 2026 to update Item 5.02. The amendment supplements the Original Form 8-K filed on August 4, 2026 by disclosing material modifications to a material compensatory plan, contract or arrangement affecting a named executive officer that were made pursuant to an agreement entered into after the August 4 filing. The company states no other changes were made to the Original Form 8-K.

Key Details

• Filing: Amendment to Form 8-K (Item 5.02) filed August 13, 2026.
• Original filing referenced: Form 8-K filed August 4, 2026.
• Disclosure: Material modifications to a material compensatory plan/contract for a named executive officer, effected by an agreement entered into subsequent to the original 8-K.
• Scope: The amendment only adds the compensation modification disclosure; no other changes to the original report were made.

Why It Matters

• Executive compensation changes are material because they affect executive incentives, potential company expenses and may influence governance perceptions.
• Retail investors should review the amended 8-K and the original August 4, 2026 filing to see the specific terms of the modification (e.g., cash, equity, severance or other changes) and assess any potential financial or governance impact.
• This is a disclosure update rather than a new operational or financial result; investors seeking details should read the full amendment on the SEC EDGAR site.